Perfusion CT allows prediction of therapy response in non-small cell lung cancer treated with conventional and anti-angiogenic chemotherapy

European Radiology

Volumn 23, Issue 8, 2013, Pages 2127-2136

  Tacelli, Nunzia ^a   Santangelo, Teresa ^a   Scherpereel, Arnaud ^a   Duhamel, Alain ^a   Deken, Valérie ^a   Klotz, Ernst ^c   Cortot, Alexis ^a   Lafitte, Jean Jacques ^a,b   Wallyn, Frédéric ^a   Remy, Jacques ^a   Remy Jardin, Martine ^a,d  

^a UNIV LILLE   (France)

^b INSERM U1019   (France)

^c Siemens Medical Solutions   (Germany)

^d LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Anti angiogenic drugs; Computed tomography; Lung; Lung cancer; Neovascularization

Indexed keywords

BEVACIZUMAB;

ADULT; ANTIANGIOGENIC THERAPY; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SIZE; CANCER STAGING; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MALE; MULTIPLE CYCLE TREATMENT; PERFUSION WEIGHTED IMAGING; PRIORITY JOURNAL; RADIOLOGICAL PARAMETERS; TREATMENT RESPONSE; TUMOR LOCALIZATION;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PERFUSION; PROSPECTIVE STUDIES; RADIOGRAPHIC IMAGE INTERPRETATION, COMPUTER-ASSISTED; REPRODUCIBILITY OF RESULTS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84880327047     PISSN: 09387994     EISSN: 14321084     Source Type: Journal    
DOI: 10.1007/s00330-013-2821-2     Document Type: Article

References (26)

1. Jain RK (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307:58-62
2. Tateishi U, Nishihara H, Tsukamoto E, Morikawa T, Tamaki N, Miyasaka K (2002) Lung tumors evaluated with FDG-PET and dynamic CT: the relationship between vascular density and glucose metabolism. J Comput Assist Tomogr 26:185-190
3. Kiessling F, Boese J, Corvinus C et al (2004) Perfusion CT in patients with advanced bronchial carcinomas: a novel chance for characterization and treatment monitoring ? Eur Radiol 14:1226-1233
4. Yi CA, Lee KS, Kim EA et al (2004) Solitary pulmonary nodules: dynamic enhanced multidetector row CT study and comparison with vascular endothelial growth factor and microvessel density. Radiology 233:191-199
5. Ovali GY, Sakar A, Göktan C et al (2007) Thorax perfusion CT in non-small cell lung cancer. Comput Med Imaging Graph 31:686-691
6. Li Y, Yang ZG, Chen TW, Chen HJ, Sun JY, Lu YR (2008) Peripheral lung carcinoma: correlation of angiogenesis and first-pass perfusion parameters of 64-detector row CT. Lung Cancer 61:44-53
7. Wang J, Wu N, Cham MD, Song Y (2009) Tumor response in patients with advanced non-small cell lung cancer: perfusion CT evaluation of chemotherapy and radiation therapy. AJR Am J Roentgenol 193:1090-1096
8. Ng QS, Goh V, Fichte H et al (2006) Lung cancer perfusion at multidetector row CT: reproducibility of whole tumor quantitative measurements. Radiology 239:547-553
9. Ng QS, Goh V, Klotz E et al (2006) Quantitative assessment of lung cancer perfusion using MDCT: does measurement reproducibility improve with greater tumor volume coverage? AJR Am J Roentgenol 187:1079-1084
10. Tacelli N, Remy-Jardin M, Copin MC et al (2010) Assessment of non-small cell lung cancer perfusion: pathologic-CT correlations in 15 patients. Radiology 257:863-871
11. Ng QS, Goh V, Carnell D et al (2007) Tumor antivascular effects of radiotherapy combined with combrestatin a4 phosphate in human non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 67:1375-1380
12. Lind JS, Meijerink MR, Dingemans AM et al (2010) Dynamic contrast-enhanced CT in patients treated with sorafenib and erlotinib for non-small cell lung cancer: a new method of monitoring treatment? Eur Radiol 20:2890-2898
13. Fraioli F, Anzidei M, Zaccagna F et al (2011) Whole-tumor perfusion CT in patients with advanced lung adenocarcinoma treated with conventional and antiangiogenetic chemotherapy: initial experience. Radiology 259:574-582
14. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
15. Sandler A, Gray R, Perry MC et al (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542-2550
16. Reck M, von Pawel J, Zatloukal P et al (2009) Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 27:1227-1234
17. Barlesi F, Balleyguier C, Besse B et al (2010) Inter- and intraobserver consistency in assessing eligibility for bevacizumab (BVZ) in non-small-cell lung cancer (NSCLC) patients with centrally located tumors. Ann Oncol 21:1682-1686
18. Goldstraw P, Crowley J, Chansky K, International association for the Study of Lung Cancer International Staging Committee et al (2007) The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol 2:706-714
19. Miles KA, Lee TY, Goh V, Experimental Cancer Medicine Centre Imaging Network Group et al (2012) Current status and guidelines for the assessment of tumor vascular support with dynamic contrast-enhanced computed tomography. Eur Radiol 22:1430-1441
20. Sabir A, Schor-Bardach R, Wilcox CJ et al (2008) Perfusion MDCT enables early detection of therapeutic response to antiangiogenic therapy. AJR Am J Roentgenol 191:133-139
21. Koukourakis MI, Mavanis I, Kouklakis G et al (2007) Early antivascular effects of bevacizumab anti-VEGF monoclonal antibody on colorectal carcinomas assessed with functional CT imaging. Am J Clin Oncol 30:315-318
22. Willett CG, Boucher Y, di Tomaso E et al (2004) Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10:145-147
23. Yabuuchi H, Hatakenaka M, Takayama K et al (2011) Non-small cell lung cancer: detection of early response to chemotherapy by using contrast-enhanced dynamic and diffusion-weighted MR imaging. Radiology 2:598-604
24. Weber WA, Petersen V, Schmidt B et al (2003) Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. J Clin Oncol 15:2651-2657
25. Lee DH, Kim SK, Lee HY et al (2009) Early prediction of response to first-line therapy using integrated 18F-FDG PET/CT for patients with advanced/metastatic non-small cell lung cancer. J Thorac Oncol 4:816-821
26. Hoang T, Dahlberg SE, Sandler AB, Brahmer JR, Shiller JH, Johnson DH (2012) Prognostic models to predict survival in non-small-cell lung cancer patients treated with first-line paclitaxel and carboplatin with or without bevacizumab. J Thorac Oncol 7:1361-1368